Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-leiden CETP mice

Toxicological Sciences

Volumn 123, Issue 1, 2011, Pages 290-303

  Bijland, Silvia ^a   Rensen, Patrick C N ^a   Pieterman, Elsbet J ^b   Maas, Annemarie C E ^b   van der Hoorn, José W ^b   van Erk, Marjan J ^b   Havekes, Louis M ^a,b   van Dijk, Ko Willems ^a   Chang, Shu Ching ^c   Ehresman, David J ^c   Butenhoff, John L ^c   Princen, Hans M G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c 3M COMPANY   (United States)

Author keywords

Cholesterol; Lipoprotein; Perfluorooctane sulfonate; PPARa; PXR; Triglyceride

Indexed keywords

ALKYL GROUP; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E3; BILE ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PERFLUOROHEXANE SULFONATE; PERFLUOROOCTANESULFONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PREGNANE X RECEPTOR; SULFONIC ACID DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FATTY LIVER; GENE CONTROL; GENE EXPRESSION; HEPATOMEGALY; HYPOLIPEMIA; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PROTEIN SYNTHESIS; TRIACYLGLYCEROL BLOOD LEVEL;

ALKANESULFONIC ACIDS; ANIMALS; CHOLESTEROL ESTER TRANSFER PROTEINS; FATTY LIVER; FLUOROCARBONS; HUMANS; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SULFONIC ACIDS; SURFACE-ACTIVE AGENTS;

MUS;

EID: 80052463195     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr142     Document Type: Article

References (54)

1. Aalto-Setala, K., Fisher, E. A., Chen, X., Chajek-Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., and Breslow, J. L. (1992). Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90, 1889-1900.
2. Berthiaume, J., and Wallace, K. B. (2002). Perfluorooctanoate, perflourooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. Toxicol. Lett. 129, 23-32.
3. Bijland, S., Pieterman, E. J., Maas, A. C., van der Hoorn, J. W., Van Erk, M. J., Van Klinken, J. B., Havekes, L. M., Willems van, D. K., Princen, H. M., and Rensen, P. C. (2010). Fenofibrate increases very low density lipoprotein-triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice. J. Biol. Chem. 285, 25168-25175.
4. Bjork, J. A., Lau, C., Chang, S. C., Butenhoff, J. L., and Wallace, K. B. (2008). Perfluorooctane sulfonate-induced changes in fetal rat liver gene expression. Toxicology 251, 8-20.
5. Bjork, J. A., and Wallace, K. B. (2009). Structure-activity relationships and human relevance for perfluoroalkyl acid-induced transcriptional activation of peroxisome proliferation in liver cell cultures. Toxicol. Sci. 111, 89-99.
6. Boorsma, A., Foat, B. C., Vis, D., Klis, F., and Bussemaker, H. J. (2005). T-profiler: scoring the activity of predefined groups of genes using gene expression data. Nucleic Acids Res. 33, W592-W595.
7. Butenhoff, J. L., Chang, S.C., Ehresman,D. J., andYork, R.G. (2009). Evaluation of potential reproductive and developmental toxicity of potassium perfluorohexanesulfonate in Sprague Dawley rats. Reprod. Toxicol. 27, 331-341.
8. Calafat, A. M., Wong, L. Y., Kuklenyik, Z., Reidy, J. A., and Needham, L. L. (2007). Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ. Health Perspect. 115, 1596-1602.
9. Chateau-Degat, M. L., Pereg, D., Dallaire, R., Ayotte, P., Dery, S., and Dewailly, E. (2010). Effects of perfluorooctanesulfonate exposure on plasma lipid levels in the Inuit population of Nunavik (Northern Quebec). Environ. Res. 110, 710-717.
10. Curran, I., Hierlihy, S. L., Liston, V., Pantazopoulos, P., Nunnikhoven, A., Tittlemier, S., Barker, M., Trick, K., and Bondy, G. (2008). Altered fatty acid homeostasis and related toxicologic sequelae in rats exposed to dietary potassium perfluorooctanesulfonate (PFOS). J. Toxicol. Environ. Health A 71, 1526-1541.
11. de Groot, P. J., Reiff, C., Mayer, C., and Muller, M. (2008). NuGO contributions to GenePattern. Genes Nutr. 3, 143-146.
12. de Haan, W., de Vries-van der Weij, J., van der Hoorn, J. W., Gautier, T., van der Hoogt, C. C., Westerterp, M., Romijn, J. A., Jukema, J. W., Havekes, L. M., Princen, H. M., et al. (2008a). Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation 117, 2515-2522.
13. de Haan, W., van der Hoogt, C. C., Westerterp, M., Hoekstra, M., Dallinga-Thie, G. M., Princen, H. M., Romijn, J. A., Jukema, J. W., Havekes, L. M., and Rensen, P. C. (2008b). Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 197, 57-63.
14. de Haan, W., de Vries-van der Weij, J., Mol, I. M., Hoekstra, M., Romijn, J. A., Jukema, J. W., Havekes, L. M., Princen, H. M., and Rensen, P. C. (2009). PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice. Biochim. Biophys. Acta 1791, 191-197.
15. D'eon, J. C., Hurley, M. D., Wallington, T. J., and Mabury, S. A. (2006). Atmospheric chemistry of N-methyl perfluorobutane sulfonamidoethanol, C4F9SO2N(CH3)CH2CH2OH: kinetics and mechanism of reaction with OH. Environ. Sci. Technol. 40, 1862-1868.
16. Egusa, G., Brady, D. W., Grundy, S. M., and Howard, B. V. (1983). Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. J. Lipid Res. 24, 1261-1267.
17. Ehresman, D. J., Froehlich, J. W., Olsen, G.W., Chang, S. C., and Butenhoff, J. L. (2007). Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. Environ. Res. 103, 176-184.
18. Giesy, J. P., and Kannan, K. (2001). Global distribution of perfluorooctane sulfonate in wildlife. Environ. Sci. Technol. 35, 1339-1342.
19. Hansen, K. J., Clemen, L. A., Ellefson, M. E., and Johnson, H. O. (2001). Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ. Sci. Technol. 35, 766-770.
20. Haughom, B., and Spydevold, O. (1992). The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim. Biophys. Acta. 1128, 65-72.
21. Ikeda, T., Aiba, K., Fukuda, K., and Tanaka, M. (1985). The induction of peroxisome proliferation in rat liver by perfluorinated fatty acids, metabolically inert derivatives of fatty acids. J. Biochem. 98, 475-482.
22. Kissa, E. (2001). In Fluorinated Surfactants and Repellents, Marcel Dekker, New York, NY.
23. Lau, C., Anitole, K., Hodes, C., Lai, D., Pfahles-Hutchens, A., and Seed, J. (2007). Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol. Sci. 99, 366-394.
24. Li, X., Catalina, F., Grundy, S. M., and Patel, S. (1996). Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. J. Lipid Res. 37, 210-220.
25. Lieder, P. H., Chang, S. C., York, R. G., and Butenhoff, J. L. (2009). Toxicological evaluation of potassium perfluorobutanesulfonate in a 90-day oral gavage study with Sprague-Dawley rats. Toxicology 255, 45-52.
26. Manal, A., Abd El-Nasser, M. A., Shaaban, A. A., and Doha, Y. A. (2009). Toxicological effects of perfluoroalkyl acids on pregnant female mice. Ass. Univ. Environ. Res. 12, 23-39.
27. Martin, M. T., Brennan, R. J., Hu, W., Ayanoglu, E., Lau, C., Ren, H., Wood, C. R., Corton, J. C., Kavlock, R. J., and Dix, D. J. (2007). Toxicogenomic study of triazole fungicides and perfluoroalkyl acids in rat livers predicts toxicity and categorizes chemicals based on mechanisms of toxicity. Toxicol. Sci. 97, 595-613.
28. Miyake, J. H., Doung, X. D., Strauss, W., Moore, G. L., Castellani, L. W., Curtiss, L. K., Taylor, J. M., and Davis, R. A. (2001). Increased production of apolipoprotein B-containing lipoproteins in the absence of hyperlipidemia in transgenic mice expressing cholesterol 7alpha-hydroxylase. J. Biol. Chem. 276, 23304-23311.
29. Moreau, A., Vilarem, M. J., Maurel, P., and Pascussi, J. M. (2008). Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol. Pharmacol. 5, 35-41.
30. Nelson, J.W.,Hatch, E. E., andWebster, T. F. (2010). Exposure to polyfluoroalkyl chemicals and cholesterol, bodyweight, and insulin resistance in the generalU.S. population. Environ. Health Perspect. 118, 197-202.
31. Olsen, G. W., Burris, J. M., Burlew, M. M., and Mandel, J. H. (2003). Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J. Occup. Environ. Med. 45, 260-270.
32. Olsen, G. W., Burris, J. M., Ehresman, D. J., Froehlich, J. W., Seacat, A. M., Butenhoff, J. L., and Zobel, L. R. (2007). Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 115, 1298-1305.
33. Olsen, G. W., Chang, S. C., Noker, P. E., Gorman, G. S., Ehresman, D. J., Lieder, P. H., and Butenhoff, J. L. (2009). A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans. Toxicology 256, 65-74.
34. Pietzsch, J., Subat, S., Nitzsche, S., Leonhardt, W., Schentke, K. U., and Hanefeld, M. (1995). Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim. Biophys. Acta 1254, 77-88.
35. Post, S. M., de Crom, R., van Haperen, R., van Tol, A., and Princen, H. M. (2003). Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein. Arterioscler. Thromb. Vasc. Biol. 23, 892-897.
36. Post, S. M., de Roos, B., Vermeulen, M., Afman, L., Jong, M. C., Dahlmans, V. E., Havekes, L. M., Stellaard, F., Katan, M. B., and Princen, H. M. (2000). Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis. Arterioscler. Thromb. Vasc. Biol. 20, 1551-1556.
37. Post, S. M., Groenendijk, M., Solaas, K., Rensen, P. C., and Princen, H. M. (2004). Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE* 3-Leiden background impairs very-low-density lipoprotein production. Arterioscler. Thromb. Vasc. Biol. 24, 768-774.
38. Rakhshandehroo, M., Hooiveld, G., Muller, M., and Kersten, S. (2009). Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One 4, e6796.
39. Reich, M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., and Mesirov, J. P. (2006). GenePattern 2.0. Nat. Genet. 38, 500-501.
40. Ren, H., Vallanat, B., Nelson, D. M., Yeung, L. W., Guruge, K. S., Lam, P. K., Lehman-McKeeman, L. D., and Corton, J. C. (2009). Evidence for the involvement of xenobiotic-responsive nuclear receptors in transcriptional effects upon perfluoroalkyl acid exposure in diverse species. Reprod. Toxicol. 27, 266-277.
41. Rensen, P. C., Herijgers, N., Netscher, M. H., Meskers, S. C., van Eck, M., and van Berkel, T. J. (1997). Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J. Lipid Res. 38, 1070-1084.
42. Seacat, A. M., Thomford, P. J., Hansen, K. J., Clemen, L. A., Eldridge, S. R., Elcombe, C. R., and Butenhoff, J. L. (2003). Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 183, 117-131.
43. Seacat, A. M., Thomford, P. J., Hansen, K. J., Olsen, G. W., Case, M. T., and Butenhoff, J. L. (2002). Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol. Sci. 68, 249-264.
44. Shipley, J. M., Hurst, C. H., Tanaka, S. S., DeRoos, F. L., Butenhoff, J. L., Seacat, A. M., and Waxman, D. J. (2004). Trans-activation of PPARalpha and induction of PPARalpha target genes by perfluorooctane-based chemicals. Toxicol. Sci. 80, 151-160.
45. Steenland, K., Tinker, S., Frisbee, S., Ducatman, A., and Vaccarino, V. (2009). Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am. J. Epidemiol. 170, 1268-1278.
46. Storey, J. D., and Tibshirani, R. (2003). Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U. S. A. 100, 9440-9445.
47. Tilton, S. C., Orner, G. A., Benninghoff, A. D., Carpenter, H. M., Hendricks, J. D., Pereira, C. B., and Williams, D. E. (2008). Genomic profiling reveals an alternate mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow trout. Environ. Health Perspect. 116, 1047-1055.
48. van der Hoogt, C. C., de Haan, W., Westerterp, M., Hoekstra, M., Dallinga-Thie, G. M., Romijn, J. A., Princen, H. M., Jukema, J. W., Havekes, L. M., and Rensen, P. C. (2007). Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J. Lipid Res. 48, 1763-1771.
49. van der Hoorn, J. W., de Haan, W., Berbee, J. F., Havekes, L. M., Jukema, J. W., Rensen, P. C., and Princen, H. M. (2008). Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden. CETP mice. Arterioscler. Thromb. Vasc. Biol. 28, 2016-2022.
50. Voshol, P. J., Rensen, P. C., van Dijk, K. W., Romijn, J. A., and Havekes, L. M. (2009). Effect of plasma triglyceride metabolism on lipid storage in adipose tissue: studies using genetically engineered mouse models. Biochim. Biophys. Acta 1791, 479-485.
51. Westerterp, M., van der Hoogt, C. C., de Haan, W., Offerman, E. H., Dallinga-Thie, G. M., Jukema, J. W., Havekes, L. M., and Rensen, P. C. (2006). Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler. Thromb. Vasc. Biol. 26, 2552-2559.
52. Xu, L., Krenitsky, D. M., Seacat, A. M., Butenhoff, J. L., and Anders, M. W. (2004). Biotransformation of N-ethyl-N-(2-hydroxyethyl)perfluorooctanesulfonamide by rat liver microsomes, cytosol, and slices and by expressed rat and human cytochromes P450. Chem. Res. Toxicol. 17, 767-775.
53. Xu, L., Krenitsky, D. M., Seacat, A. M., Butenhoff, J. L., Tephly, T. R., and Anders, M. W. (2006). N-glucuronidation of perfluorooctanesulfonamide by human, rat, dog, and monkey liver microsomes and by expressed rat and human UDP-glucuronosyltransferases. Drug Metab. Dispos. 34, 1406-1410.
54. Zhou, J., Zhai, Y., Mu, Y., Gong, H., Uppal, H., Toma, D., Ren, S., Evans, R. M., and Xie, W. (2006). A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 281, 15013-15020.